CN116096725A - 用于调节剪接的化合物和方法 - Google Patents

用于调节剪接的化合物和方法 Download PDF

Info

Publication number
CN116096725A
CN116096725A CN202180040958.1A CN202180040958A CN116096725A CN 116096725 A CN116096725 A CN 116096725A CN 202180040958 A CN202180040958 A CN 202180040958A CN 116096725 A CN116096725 A CN 116096725A
Authority
CN
China
Prior art keywords
compound
heterocyclyl
heteroaryl
aryl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180040958.1A
Other languages
English (en)
Chinese (zh)
Inventor
D.雷诺兹
M.W.塞勒
A.A.阿格拉瓦尔
F.维尔兰科特
P.史密斯
S.莱格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Remix Medical
Original Assignee
Remix Medical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remix Medical filed Critical Remix Medical
Publication of CN116096725A publication Critical patent/CN116096725A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Replacement Of Web Rolls (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
CN202180040958.1A 2020-04-08 2021-04-08 用于调节剪接的化合物和方法 Pending CN116096725A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063007327P 2020-04-08 2020-04-08
US63/007,327 2020-04-08
US202063043920P 2020-06-25 2020-06-25
US63/043,920 2020-06-25
US202063072873P 2020-08-31 2020-08-31
US63/072,873 2020-08-31
US202063126493P 2020-12-16 2020-12-16
US63/126,493 2020-12-16
PCT/US2021/026435 WO2021207530A1 (en) 2020-04-08 2021-04-08 Compounds and methods for modulating splicing

Publications (1)

Publication Number Publication Date
CN116096725A true CN116096725A (zh) 2023-05-09

Family

ID=75747105

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202180040958.1A Pending CN116096725A (zh) 2020-04-08 2021-04-08 用于调节剪接的化合物和方法
CN202180040768.XA Pending CN116134036A (zh) 2020-04-08 2021-04-08 用于调节剪接的化合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202180040768.XA Pending CN116134036A (zh) 2020-04-08 2021-04-08 用于调节剪接的化合物和方法

Country Status (14)

Country Link
US (2) US20240287097A1 (enExample)
EP (2) EP4132936A1 (enExample)
JP (2) JP7797407B2 (enExample)
KR (2) KR20230004575A (enExample)
CN (2) CN116096725A (enExample)
AU (2) AU2021251220A1 (enExample)
BR (2) BR112022020418A2 (enExample)
CA (2) CA3175205A1 (enExample)
CL (1) CL2022002779A1 (enExample)
CO (1) CO2022015926A2 (enExample)
CR (1) CR20220567A (enExample)
IL (1) IL297149A (enExample)
MX (2) MX2022012677A (enExample)
WO (2) WO2021207550A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020001425A (es) 2017-08-04 2020-08-06 Skyhawk Therapeutics Inc Metodos y composiciones para modular el empalme.
WO2020163248A1 (en) 2019-02-04 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
WO2020163541A1 (en) 2019-02-05 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
JP7603594B2 (ja) 2019-02-06 2024-12-20 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングを調節するための方法および組成物
IL297963A (en) 2020-05-07 2023-01-01 Adorx Therapeutics Ltd Antagonists of the adenosine a2a receptor
WO2021231571A1 (en) 2020-05-13 2021-11-18 Chdi Foundation, Inc. Htt modulators for treating huntington's disease
EP4308577B1 (en) * 2021-03-17 2024-12-25 F. Hoffmann-La Roche AG New thiadiazolopyrimidone derivatives
CR20230437A (es) * 2021-03-17 2023-10-16 Hoffmann La Roche Nuevos derivados de tiazolopirimidinona
EP4308572B1 (en) * 2021-03-17 2025-04-23 F. Hoffmann-La Roche AG New thienopyrimidinone derivatives
TW202330552A (zh) * 2021-10-13 2023-08-01 美商雷密克斯醫療公司 調節剪接之化合物及方法
AU2022394333A1 (en) 2021-11-17 2024-06-27 Chdi Foundation, Inc. HTT modulators for treating Huntington’s disease
JP2024541481A (ja) * 2021-11-24 2024-11-08 リミックス セラピューティクス インコーポレイテッド スプライシングを調整するための化合物及び方法
CN115112899B (zh) * 2022-06-15 2024-08-16 四川大学华西医院 检测羧肽酶a4的试剂和/或系统在制备恶性胸腔积液筛查产品中的用途
CN121653249B (zh) * 2026-02-09 2026-05-26 中国医学科学院医学生物学研究所 Dnal1基因作为靶点在筛选防治寨卡病毒或2型登革病毒感染药物中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160376289A1 (en) * 2014-04-23 2016-12-29 Mitsubishi Tanabe Pharma Corporation Novel bicyclic or tricyclic heterocyclic compound
JP2017081908A (ja) * 2015-10-22 2017-05-18 田辺三菱製薬株式会社 医薬組成物
WO2018054846A1 (de) * 2016-09-23 2018-03-29 Bayer Aktiengesellschaft N3-cyclisch substituierte thienouracile und ihre verwendung
WO2018237084A1 (en) * 2017-06-21 2018-12-27 SHY Therapeutics LLC COMPOUNDS INTERACTING WITH RAS SUPERFAMIL FOR USE IN THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES AND FIBROTIC DISEASES
CA3105174A1 (en) * 2018-06-27 2020-01-02 Reborna Biosciences, Inc. Prophylactic or therapeutic agent for spinal muscular atrophy

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB242502A (en) * 1925-03-10 1925-11-12 Hoe & Co R Improvements in stapling and folding mechanism
JPS57142989A (en) * 1981-02-27 1982-09-03 Dai Ichi Seiyaku Co Ltd Thiazolopyrimidine derivative
JPS58177997A (ja) * 1982-04-12 1983-10-18 Dai Ichi Seiyaku Co Ltd チアジアゾロピリミジノン誘導体
ES2016293B3 (es) * 1986-03-19 1990-11-01 Kumiai Chemical Industry Co Fungicida agricola-horticola.
TW449600B (en) * 1994-04-19 2001-08-11 Takeda Chemical Industries Ltd Condensed-ring thiophene derivatives, their production and use
US6153614A (en) 1998-07-16 2000-11-28 Abbott Laboratories Piperazinyl pyrimidine dione compounds selective for adrenoceptors
AR038118A1 (es) 2002-01-14 2004-12-29 Upjohn Co Compuestos derivados de la bencinamida del acido 7-oxo-4,7-dihidrotien[2,3-b[piridin-6-carboxilico 3-sustituido que son utiles como antivirales
US20060194871A1 (en) 2003-04-11 2006-08-31 Barvian Kevin K Heterocyclic mchr1 antagoists
WO2005047293A1 (en) * 2003-11-07 2005-05-26 Neurocrine Biosciences, Inc. Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
US7745447B2 (en) * 2005-10-26 2010-06-29 Bristol-Myers Squibb Company Substituted thieno[3,2-D]pyrimidines as non-basic melanin concentrating hormone receptor-1 antagonists
US8618115B2 (en) 2005-10-26 2013-12-31 Bristol-Myers Squibb Company Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
KR100846988B1 (ko) 2006-03-06 2008-07-16 제일약품주식회사 신규한 티에노피리미딘 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 함유하는 약학조성물
WO2008057601A2 (en) * 2006-11-08 2008-05-15 The Rockefeller University Organic compounds
EP2593106A4 (en) 2010-07-16 2014-01-01 Univ Rockefeller ORGANIC CONNECTIONS
JP2014519519A (ja) 2011-06-15 2014-08-14 タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規３，４，４ａ，１０ｂ−テトラヒドロ−１Ｈ−チオピラノ［４，３−ｃ］イソキノリン化合物
US20130102601A1 (en) 2011-10-21 2013-04-25 F. Hoffmann-La Roche Ltd Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2013109632A2 (en) 2012-01-16 2013-07-25 The Rockefeller University Organic compounds
EP3406252B1 (en) 2012-02-10 2020-05-13 PTC Therapeutics, Inc. Compounds for treating spinal muscular atrophy
US8729263B2 (en) 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
AU2015261046C1 (en) 2014-05-15 2019-07-25 F. Hoffmann-La Roche Ag Compounds for treating spinal muscular atrophy
WO2015185531A1 (de) 2014-06-05 2015-12-10 Bayer Cropscience Aktiengesellschaft Bicyclische verbindungen als schädlingsbekämpfungsmittel
EP3256126B1 (en) 2015-02-09 2024-03-27 F. Hoffmann-La Roche AG Compounds for the treatment of cancer
EP3310169B1 (en) 2015-05-30 2023-05-17 PTC Therapeutics, Inc. Methods for modulating rna splicing
CN106279211B (zh) 2015-06-03 2020-09-15 北京大学 一种噻唑并嘧啶酮化合物及其制备方法和应用
AR106472A1 (es) * 2015-10-26 2018-01-17 Gilead Apollo Llc Inhibidores de acc y usos de los mismos
CA3119019C (en) 2015-12-10 2024-06-11 Ptc Therapeutics, Inc. Compounds and methods for treating huntington's disease
JP2019535789A (ja) 2016-11-28 2019-12-12 ピーティーシー セラピューティクス，インコーポレーテッド Ｒｎａスプライシングを調節する方法
CN111372611A (zh) 2017-06-14 2020-07-03 Ptc医疗公司 修饰rna剪接的方法
MX2020001425A (es) 2017-08-04 2020-08-06 Skyhawk Therapeutics Inc Metodos y composiciones para modular el empalme.
US20230152257A1 (en) 2017-09-25 2023-05-18 Skyhawk Therapeutics, Inc. Methods and compositions for screening and identification of splicing
US10584133B2 (en) 2018-03-30 2020-03-10 Biotheryx, Inc. Thienopyrimidinone compounds
JP2021521200A (ja) 2018-04-10 2021-08-26 スカイホーク・セラピューティクス・インコーポレーテッド 癌の処置のための化合物
CR20230437A (es) * 2021-03-17 2023-10-16 Hoffmann La Roche Nuevos derivados de tiazolopirimidinona
EP4308577B1 (en) * 2021-03-17 2024-12-25 F. Hoffmann-La Roche AG New thiadiazolopyrimidone derivatives

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160376289A1 (en) * 2014-04-23 2016-12-29 Mitsubishi Tanabe Pharma Corporation Novel bicyclic or tricyclic heterocyclic compound
CN106661017A (zh) * 2014-04-23 2017-05-10 田边三菱制药株式会社 新型二环性或三环性杂环化合物
JP2017081908A (ja) * 2015-10-22 2017-05-18 田辺三菱製薬株式会社 医薬組成物
WO2018054846A1 (de) * 2016-09-23 2018-03-29 Bayer Aktiengesellschaft N3-cyclisch substituierte thienouracile und ihre verwendung
WO2018237084A1 (en) * 2017-06-21 2018-12-27 SHY Therapeutics LLC COMPOUNDS INTERACTING WITH RAS SUPERFAMIL FOR USE IN THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES AND FIBROTIC DISEASES
CA3105174A1 (en) * 2018-06-27 2020-01-02 Reborna Biosciences, Inc. Prophylactic or therapeutic agent for spinal muscular atrophy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EMMANUEL PINARD ET AL.: "Discovery of a Novel Class of Survival Motor Neuron 2 Splicing Modifiers for the Treatment of Spinal Muscular Atrophy", 《J. MED. CHEM.》, 25 April 2017 (2017-04-25), pages 4444 *
GIOVANNI PUGLISI ET AL.: "Synthesis and biological evaluation of 2-alkoxyphenyl-6-(substituted phenyl)-1, 3, 4-thiadiazole-[3, 2-a]-s-triazin-5, 7-diones and 1-(alkyl and substituted phenyl)-3-[5-alkoxyphenyl-1, 3, 4-thia- and oxadiazol-2-yl]-ureas", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》, 31 December 1989 (1989-12-31), pages 277 - 286 *
JINGXIN WANG ET AL.: "Mechanistic studies of a small-molecule modulator of SMN2 splicing", 《PNAS》, 30 April 2018 (2018-04-30), pages 4604 *

Also Published As

Publication number Publication date
IL297149A (en) 2022-12-01
EP4132936A1 (en) 2023-02-15
BR112022020337A2 (pt) 2022-12-13
US20240279239A1 (en) 2024-08-22
WO2021207530A8 (en) 2021-12-02
KR20230005210A (ko) 2023-01-09
EP4132935A1 (en) 2023-02-15
BR112022020418A2 (pt) 2023-05-02
MX2022012676A (es) 2023-01-11
CL2022002779A1 (es) 2023-04-28
US20240287097A1 (en) 2024-08-29
CA3175193A1 (en) 2021-10-14
AU2021251220A1 (en) 2022-11-03
WO2021207550A1 (en) 2021-10-14
JP7882782B2 (ja) 2026-06-30
AU2021253571A1 (en) 2022-11-10
WO2021207530A1 (en) 2021-10-14
JP2023520924A (ja) 2023-05-22
MX2022012677A (es) 2023-01-11
CO2022015926A2 (es) 2022-11-29
CR20220567A (es) 2023-01-13
JP2023520925A (ja) 2023-05-22
CA3175205A1 (en) 2021-10-14
CN116134036A (zh) 2023-05-16
JP7797407B2 (ja) 2026-01-13
KR20230004575A (ko) 2023-01-06

Similar Documents

Publication Publication Date Title
JP7736700B2 (ja) 複素環アミド及びスプライシングを調節するためのその使用
CN116134036A (zh) 用于调节剪接的化合物和方法
TWI912305B (zh) 調節剪接之化合物及方法
US20230142338A1 (en) Thiophenyl derivatives useful for modulating nucleic acid splicing
KR20220158237A (ko) 스플라이싱을 조절하기 위한 화합물 및 방법
IL299543A (en) 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases
CN117015536A (zh) 作为核酸剪接和增殖性疾病治疗的调节剂的2-(吲唑-5-基)-6-(哌啶-4-基)-1,7-萘啶衍生物及相关化合物
WO2024182747A2 (en) Compounds and methods for modulating splicing
TW202328135A (zh) 調節剪接之化合物及用途
TW202319047A (zh) 調節剪接之化合物及用途
CN116940578A (zh) 5-[5-(哌啶-4-基)噻吩并[3,2-c]吡唑-2-基]吲唑衍生物和相关化合物作为调节剂用于剪接核酸和治疗增殖性疾病
WO2024182788A1 (en) Compounds and methods for modulating splicing
CN118234724A (zh) 用于调节剪接的化合物和方法
KR20260047325A (ko) 스플라이싱을 조절하기 위한 화합물 및 방법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination